Nektar’s pulmonary platform will be used to deliver amikacin, an aminoglycoside antibiotic.

Bayer HealthCare and Nektar Therapeutics will work together to develop and commercialize an adjunctive treatment of Gram-negative pneumonias. NKTR-061 is currently in Phase II a trials. Nektar will utilize its pulmonary technology to deliver this specially formulated amikacin, an aminoglycoside antibiotic, for inhalation deep into the lung.

As part of this agreement, Nektar will receive milestone payments of up to $175 million. This includes an upfront payment of $50 million. Subsequent to the successful clinical and regulatory development of the product, Bayer HealthCare and Nektar have agreed co-promote the product in the U.S. and to share profits. For sales outside the U.S., Nektar will receive tiered royalties up to a maximum of 30%.

Bayer HealthCare is responsible for the global clinical development, regulatory strategy, manufacturing, and marketing of the product, with Nektar participating in all aspects of decision-making and governance.

This collaboration is Bayer HealthCare’s second with Nektar. In 2005, Bayer and Nektar agreed to collaborate on the joint development of inhaled ciprofloxacin as a potential dry powder therapy for treating pseudomonal infections in patients suffering from cystic fibrosis.

Previous articleMedical Research Council Technology Inks Collaboration with Intellect Neurosciences Related to Alzheimer’s
Next articleMitoPharm Licenses New Extraction Method